Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 0.70 |
| ▸ | BCL2 | P10415 | 14/20 | 0.59 |
| ▸ | BCL2L2 | Q92843 | 7/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31570889 | 0.99 | BCL2L1 (0.69) | BCL2L1BCL2BCL2L2MCL1DOT1L | |
| SCHEMBL3823004 | 0.99 | BCL2L1 (0.69) | BCL2L1BCL2BCL2L2MCL1DOT1L | |
| SCHEMBL4747130 | 0.99 | BCL2L1 (0.69) | BCL2L1BCL2BCL2L2MCL1DOT1L | |
| SCHEMBL3822342 | 0.99 | BCL2L1 (0.69) | BCL2L1BCL2BCL2L2MCL1DOT1L | |
| SCHEMBL31570886 | 0.98 | BCL2L1 (0.70) | BCL2L1BCL2BCL2L2MCL1DOT1L | |
| SCHEMBL25422833 | 0.93 | BCL2L1 (0.68) | BCL2L1BCL2BCL2L2MCL1ALB | |
| SCHEMBL25422835 | 0.93 | BCL2L1 (0.68) | BCL2L1BCL2BCL2L2MCL1ALB | |
| SCHEMBL3819345 | 0.93 | BCL2L1 (0.72) | BCL2L1BCL2BCL2L2MCL1ALB | |
| SCHEMBL555323 | 0.93 | BCL2L1 (0.72) | BCL2L1BCL2BCL2L2MCL1ALB | |
| SCHEMBL555322 | 0.93 | BCL2L1 (0.72) | BCL2L1BCL2BCL2L2MCL1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-05-15 | — | — | US | disclosed |
| EP-1953161-B1 | New tricyclic derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008110691-A1 | NOVEL TRICYCLIC DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2008-09-18 | — | — | WO | disclosed |
| US-20080188460-A1 | Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2008-08-07 | — | — | US | disclosed |
| EP-1953161-A1 | New tricyclic derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | BCL2, BCL2L2, BCL2L1 | BCL2L1 3/4885BCL2 1/4885BCL2L2 2/4885 |
| US-20080188460-A1 | Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them | BAX, BCL2, CASP3 | BCL2L1 45/4885BCL2 2/4885BCL2L2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.